Document is current
Any future updates will be listed below
-
Authors
Benusiglio, Patrick R. https://orcid.org/0000-0003-1003-1997
Dardenne, Antoine
Fallet, Vincent
Cadranel, Jacques
- License Information
-
More Information
Article History
Received: 7 September 2023
Accepted: 13 September 2023
First Online: 28 September 2023
Competing interests
: PRB has received honoraria from AstraZeneca and MSD, the manufacturers or olaparib, a drug that targets <i>BRCA2</i>-deficient cancers.
